

Prasad S Adusumilli

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3208991/publications.pdf>

Version: 2024-02-01

226
papers

13,497
citations

19608

61
h-index

28224

105
g-index

228
all docs

228
docs citations

228
times ranked

13967
citing authors

#	ARTICLE	IF	CITATIONS
1	Commentary: Regional oncolytics for pleural malignancies. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 163, e330-e331.	0.4	0
2	Shape-Sensing Robotic-Assisted Bronchoscopy in the Diagnosis of Pulmonary Parenchymal Lesions. <i>Chest</i> , 2022, 161, 572-582.	0.4	82
3	Tumor and Tumor-Associated Macrophage Programmed Death-Ligand 1 Expression Is Associated With Adjuvant Chemotherapy Benefit in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2022, 17, 89-102.	0.5	16
4	Improved prediction of immune checkpoint blockade efficacy across multiple cancer types. <i>Nature Biotechnology</i> , 2022, 40, 499-506.	9.4	110
5	Image-guided interventional radiological delivery of chimeric antigen receptor (CAR) T cells for pleural malignancies in a phase I/II clinical trial. <i>Lung Cancer</i> , 2022, 165, 1-9.	0.9	15
6	Expanding the role of interventional oncology for advancing precision immunotherapy of solid tumors. <i>Molecular Therapy - Oncolytics</i> , 2022, 24, 194-204.	2.0	7
7	Patterns and influence of nodal metastases after neoadjuvant chemoradiation and R0 resection in esophageal adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2022, 164, 411-419.	0.4	4
8	Expression of the mono-ADP-ribosyltransferase ART1 by tumor cells mediates immune resistance in non-small cell lung cancer. <i>Science Translational Medicine</i> , 2022, 14, eabe8195.	5.8	16
9	Regional CAR T cell therapy: An ignition key for systemic immunity in solid tumors. <i>Cancer Cell</i> , 2022, 40, 569-574.	7.7	24
10	Advancing together and moving forward: Combination gene and cellular immunotherapies. <i>Molecular Therapy - Oncolytics</i> , 2022, 25, 330-334.	2.0	2
11	Evolving Landscape of Initial Treatments for Patients with Malignant Pleural Mesotheliomas: Clinical Trials to Clinical Practice. <i>Oncologist</i> , 2022, 27, 610-614.	1.9	2
12	Two-Year Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy. <i>Annals of Thoracic Surgery</i> , 2021, 112, 880-889.	0.7	13
13	Intentional Segmentectomy for Clinical T1 N0 Non-small Cell Lung Cancer: Survival Differs by Segment. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1028-1035.	0.7	10
14	Performance Comparison Between SURPAS and ACS NSQIP Surgical Risk Calculator in Pulmonary Resection. <i>Annals of Thoracic Surgery</i> , 2021, 111, 1643-1651.	0.7	7
15	Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity. <i>Nature Protocols</i> , 2021, 16, 1331-1342.	5.5	48
16	Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors. <i>Nature Communications</i> , 2021, 12, 729.	5.8	212
17	<i>KRAS</i> G12C Mutation Is Associated with Increased Risk of Recurrence in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2021, 27, 2604-2612.	3.2	20
18	A Genomic-Pathologic Annotated Risk Model to Predict Recurrence in Early-Stage Lung Adenocarcinoma. <i>JAMA Surgery</i> , 2021, 156, e205601.	2.2	52

#	ARTICLE	IF	CITATIONS
19	Comprehensive Molecular and Clinicopathologic Analysis of 200 Pulmonary Invasive Mucinous Adenocarcinomas Identifies Distinct Characteristics of Molecular Subtypes. <i>Clinical Cancer Research</i> , 2021, 27, 4066-4076.	3.2	45
20	CAR T-cell therapy for pleural mesothelioma: Rationale, preclinical development, and clinical trials. <i>Lung Cancer</i> , 2021, 157, 48-59.	0.9	16
21	Preoperative clinical and tumor genomic features associated with pathologic lymph node metastasis in clinical stage I and II lung adenocarcinoma. <i>Npj Precision Oncology</i> , 2021, 5, 70.	2.3	8
22	Intraoperative opioid exposure, tumour genomic alterations, and survival differences in people with lung adenocarcinoma. <i>British Journal of Anaesthesia</i> , 2021, 127, 75-84.	1.5	33
23	A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti-PD-1 Agent Pembrolizumab. <i>Cancer Discovery</i> , 2021, 11, 2748-2763.	7.7	222
24	Spread Through Air Spaces (STAS) in Non-Small Cell Lung Carcinoma. <i>American Journal of Surgical Pathology</i> , 2021, 45, 1509-1515.	2.1	14
25	Intraoperative ketorolac may interact with patient-specific tumour genomics to modify recurrence risk in lung adenocarcinoma: an exploratory analysis. <i>British Journal of Anaesthesia</i> , 2021, 127, e82-e85.	1.5	5
26	The use of a next-generation sequencing-derived machine-learning risk-prediction model (OncoCast-MPM) for malignant pleural mesothelioma: a retrospective study. <i>The Lancet Digital Health</i> , 2021, 3, e565-e576.	5.9	23
27	Lung Ablation with Irreversible Electroporation Promotes Immune Cell Infiltration by Sparing Extracellular Matrix Proteins and Vasculature: Implications for Immunotherapy. <i>Bioelectricity</i> , 2021, 3, 204-214.	0.6	9
28	Depletion of high-content CD14+ cells from apheresis products is critical for successful transduction and expansion of CAR T cells during large-scale cGMP manufacturing. <i>Molecular Therapy - Methods and Clinical Development</i> , 2021, 22, 377-387.	1.8	17
29	Imaging CAR T-cell kinetics in solid tumors: Translational implications. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 355-367.	2.0	20
30	Primary lung cancer in women after previous breast cancer. <i>BJS Open</i> , 2021, 5, .	0.7	6
31	Arming T cells to infiltrate pancreatic tumours. <i>Nature Biomedical Engineering</i> , 2021, 5, 1243-1245.	11.6	3
32	Long-term assessment of efficacy with a novel Thoracic Survivorship Program for patients with lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2021, , .	0.4	5
33	Chimeric antigen receptor T-cell therapy plus checkpoint blockade in thoracic cancers. <i>Clinical Advances in Hematology and Oncology</i> , 2021, 19, 295-297.	0.3	0
34	V-domain Ig-containing suppressor of T-cell activation (VISTA), a potentially targetable immune checkpoint molecule, is highly expressed in epithelioid malignant pleural mesothelioma. <i>Modern Pathology</i> , 2020, 33, 303-311.	2.9	65
35	Prevalence of Occult Peribronchial N1 Nodal Metastasis in Peripheral Clinical N0 Small ($\geq 2\text{ cm}$) Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2020, 109, 270-276.	0.7	24
36	Three-Dimensional Histologic, Immunohistochemical, and Multiplex Immunofluorescence Analyses of Dynamic Vessel Co-Option of Spread Through Air Spaces in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 589-600.	0.5	55

#	ARTICLE	IF	CITATIONS
37	Long-term, disease-specific outcomes of thymic malignancies presenting with de novo pleural metastasis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2020, 159, 705-714.e1.	0.4	18
38	Decreasing use of epidural analgesia with increasing minimally invasive lobectomy: Impact on postoperative morbidity. <i>Lung Cancer</i> , 2020, 139, 68-72.	0.9	11
39	Unique Considerations for Females Undergoing Esophagectomy. <i>Annals of Surgery</i> , 2020, 272, 113-117.	2.1	13
40	Commentary: Long-term in vivo microscopy of CAR T cell dynamics during eradication of CNS lymphoma in mice. <i>Frontiers in Immunology</i> , 2020, 11, 1503.	2.2	2
41	The Underlying Tumor Genomics of Predominant Histologic Subtypes in Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1844-1856.	0.5	83
42	gC1qR/HABP1/p32 Is a Potential New Therapeutic Target Against Mesothelioma. <i>Frontiers in Oncology</i> , 2020, 10, 1413.	1.3	13
43	Is Routine Chest Radiography Necessary After Endobronchial Ultrasound-guided Fine Needle Aspiration?. <i>Annals of Thoracic Surgery</i> , 2020, 112, 467-472.	0.7	0
44	A prospective trial of intraoperative tissue oxygenation measurement and its association with anastomotic leak rate after Ivor Lewis esophagectomy. <i>Journal of Thoracic Disease</i> , 2020, 12, 1449-1459.	0.6	2
45	The Newly Described Filigree Pattern Is an Expansion of the Micropapillary Adenocarcinoma Concept Rather Than a Proposed New Subtype. <i>Journal of Thoracic Oncology</i> , 2020, 15, e121-e124.	0.5	5
46	Spread Through Air Spaces Is Prognostic in Neuroendocrine Lung Tumors and Can Be Distinguished From Artifacts. <i>Journal of Thoracic Oncology</i> , 2020, 15, e118-e120.	0.5	6
47	IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy. <i>Journal of Thoracic Oncology</i> , 2020, 15, 709-740.	0.5	205
48	Tumor Spread Through Air Spaces Is a Predictor of Occult Lymph Node Metastasis in Clinical Stage IA Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2020, 15, 792-802.	0.5	43
49	Histology Subtyping From Core Needle Biopsy. <i>Annals of Thoracic Surgery</i> , 2020, 109, 1947-1948.	0.7	0
50	Propensity-matched Analysis Demonstrates Long-term Risk of Respiratory and Cardiac Mortality After Pneumonectomy Compared With Lobectomy for Lung Cancer. <i>Annals of Surgery</i> , 2020, Publish Ahead of Print, .	2.1	4
51	Regional Gene Therapy for Cancer. , 2020, , 55-71.		0
52	Reply to Waller et Al. Standardizing Surgical Treatment for Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2020, 15, e75-e77.	0.5	1
53	Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery. <i>Translational Lung Cancer Research</i> , 2019, 8, S373-S377.	1.3	7
54	Mesothelioma: Scientific clues for prevention, diagnosis, and therapy. <i>Ca-A Cancer Journal for Clinicians</i> , 2019, 69, 402-429.	157.7	306

#	ARTICLE	IF	CITATIONS
55	Utility of Core Biopsy Specimen to Identify Histologic Subtype and Predict Outcome for Lung Adenocarcinoma. <i>Annals of Thoracic Surgery</i> , 2019, 108, 392-398.	0.7	18
56	A Proposed System Toward Standardizing Surgical-Based Treatments for Malignant Pleural Mesothelioma, From the Joint National Cancer Institute–International Association for the Study of Lung Cancer–Mesothelioma Applied Research Foundation Taskforce. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1343-1353.	0.5	41
57	Spread Through Air Spaces (STAS) Is Prognostic in Atypical Carcinoid, Large Cell Neuroendocrine Carcinoma, and Small Cell Carcinoma of the Lung. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1583-1593.	0.5	55
58	Expansion of the Concept of Micropapillary Adenocarcinoma to Include a Newly Recognized Filigree Pattern as Well as the Classical Pattern Based on 1468 Stage I Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1948-1961.	0.5	35
59	Prevalence and Preliminary Validation of Screening Criteria to Identify Carriers of Germline BAP1 Mutations. <i>Journal of Thoracic Oncology</i> , 2019, 14, 1989-1994.	0.5	10
60	Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors. <i>Cancer Cell</i> , 2019, 36, 471-482.	7.7	280
61	Globular C1q Receptor (gC1qR/p32/HABP1) Is Overexpressed in Malignant Pleural Mesothelioma and Is Associated With Increased Survival in Surgical Patients Treated With Chemotherapy. <i>Frontiers in Oncology</i> , 2019, 9, 1042.	1.3	10
62	Commentary: Return to intended radiation therapy—Criteria for resection?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 930-931.	0.4	0
63	<p>Reporting net survival in populations: a sensitivity analysis in lung cancer demonstrates the differential implications of reporting relative survival and cause-specific survival</p>. <i>Clinical Epidemiology</i> , 2019, Volume 11, 781-792.	1.5	9
64	Analysis of Tumor Genomic Pathway Alterations Using Broad-Panel Next-Generation Sequencing in Surgically Resected Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2019, 25, 7475-7484.	3.2	30
65	Early Quality of Life Outcomes After Robotic-Assisted Minimally Invasive and Open Esophagectomy. <i>Annals of Thoracic Surgery</i> , 2019, 108, 920-928.	0.7	54
66	Perioperative blood transfusion has a dose-dependent relationship with disease recurrence and survival in patients with non–small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 2469-2477.e10.	0.4	32
67	Initial results of pulmonary resection after neoadjuvant nivolumab in patients with resectable non–small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 158, 269-276.	0.4	218
68	Predicting spread through air spaces (STAS) preoperatively: can imaging help?. <i>Journal of Thoracic Disease</i> , 2019, 11, S1938-S1941.	0.6	3
69	Does pyloric drainage have a role in the era of minimally invasive esophagectomy?. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2019, 33, 3218-3227.	1.3	17
70	Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 482-493.	0.5	81
71	Outcomes after neoadjuvant or adjuvant chemotherapy for cT2-4N0-1 non–small cell lung cancer: A propensity-matched analysis. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2019, 157, 743-753.e3.	0.4	30
72	Procedure-Specific Risk Prediction for Recurrence in Patients Undergoing Lobectomy or Sublobar Resection for Small (cm) Lung Adenocarcinoma: An International Cohort Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 72-86.	0.5	41

#	ARTICLE	IF	CITATIONS
73	Lobectomy Is Associated with Better Outcomes than Sublobar Resection in Spread through Air Spaces (STAS)-Positive T1 Lung Adenocarcinoma: A Propensity Score-Matched Analysis. <i>Journal of Thoracic Oncology</i> , 2019, 14, 87-98.	0.5	153
74	Minimally Invasive Lobectomy Is Associated With Lower Noncancer-specific Mortality in Elderly Patients. <i>Annals of Surgery</i> , 2019, 270, 1161-1169.	2.1	27
75	Regional delivery of mesothelin-targeted CAR T cells for pleural cancers: Safety and preliminary efficacy in combination with anti-PD-1 agent. <i>Journal of Clinical Oncology</i> , 2019, 37, 2511-2511.	0.8	75
76	What CT characteristics of lepidic predominant pattern lung adenocarcinomas correlate with invasiveness on pathology?. <i>Lung Cancer</i> , 2018, 118, 83-89.	0.9	27
77	Tracing the origin, tracking the evolution, and the treatment of the future. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1203-1204.	0.4	0
78	Factors associated with distant recurrence following R0 lobectomy for pN0 lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 1212-1224.e3.	0.4	23
79	Nuclear grade and necrosis predict prognosis in malignant epithelioid pleural mesothelioma: a multi-institutional study. <i>Modern Pathology</i> , 2018, 31, 598-606.	2.9	70
80	Safety and Feasibility of Lung Resection After Immunotherapy for Metastatic or Unresectable Tumors. <i>Annals of Thoracic Surgery</i> , 2018, 106, 178-183.	0.7	96
81	Driving CARs on the uneven road of antigen heterogeneity in solid tumors. <i>Current Opinion in Immunology</i> , 2018, 51, 103-110.	2.4	88
82	Definitive chemoradiotherapy versus neoadjuvant chemoradiotherapy followed by surgery for stage II to III esophageal squamous cell carcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 2710-2721.e3.	0.4	41
83	Preponderance of High-Grade Histologic Subtype in Autologous Metastases in Lung Adenocarcinoma. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2018, 197, 816-818.	2.5	7
84	Pulmonary large cell neuroendocrine carcinoma with adenocarcinoma-like features: napsin A expression and genomic alterations. <i>Modern Pathology</i> , 2018, 31, 111-121.	2.9	50
85	New staging system for pulmonary neuroendocrine tumors: A clinical and pathologic necessity. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 155, 367-368.	0.4	3
86	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. <i>Journal of Thoracic Oncology</i> , 2018, 13, 16-26.	0.5	72
87	BRMS1 Expression in Surgically Resected Lung Adenocarcinoma Predicts Future Metastases and Is Associated with a Poor Prognosis. <i>Journal of Thoracic Oncology</i> , 2018, 13, 73-84.	0.5	17
88	Micropapillary and/or Solid Histologic Subtype Based on Pre-Treatment Biopsy Predicts Local Recurrence After Thermal Ablation of Lung Adenocarcinoma. <i>CardioVascular and Interventional Radiology</i> , 2018, 41, 253-259.	0.9	19
89	Immunotherapy for thoracic malignancies. <i>Indian Journal of Thoracic and Cardiovascular Surgery</i> , 2018, 34, 54-64.	0.2	0
90	Implications of the Eighth Edition of the TNM Proposal: Invasive Versus Total Tumor Size for the T Descriptor in Pathologic Stage I-IIA Lung Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1919-1929.	0.5	32

#	ARTICLE	IF	CITATIONS
91	Current and Future Management of Malignant Mesothelioma: A Consensus Report from the National Cancer Institute Thoracic Malignancy Steering Committee, International Association for the Study of Lung Cancer, and Mesothelioma Applied Research Foundation. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1655-1667.	0.5	85
92	Postoperative Radiotherapy for Surgically Resected ypN2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 848-855.	0.7	17
93	Competing risks and cancer-specific mortality: why it matters. <i>Oncotarget</i> , 2018, 9, 7272-7273.	0.8	27
94	Histologic subtyping in pathologic stage I-IIA lung adenocarcinoma provides risk-based stratification for surveillance. <i>Oncotarget</i> , 2018, 9, 35742-35751.	0.8	24
95	Long-term Survival Based on the Surgical Approach to Lobectomy For Clinical Stage I Nonsmall Cell Lung Cancer. <i>Annals of Surgery</i> , 2017, 265, 431-437.	2.1	248
96	Pulmonary metastasectomy with therapeutic intent for soft-tissue sarcoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 319-330.e1.	0.4	96
97	Hot nodules and histologic features: The emerging story of stage IA lung adenocarcinoma. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 154, 1075-1076.	0.4	0
98	Heart Dosimetry is Correlated With Risk of Radiation Pneumonitis After Lung-Sparing Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 61-69.	0.4	19
99	CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. <i>Translational Research</i> , 2017, 187, 1-10.	2.2	83
100	OA20.03 Tumoral IL-7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy. <i>Journal of Thoracic Oncology</i> , 2017, 12, S323.	0.5	1
101	MA12.10 Histological Subtyping of Matched Primary and Metastases Sites in Lung Adenocarcinoma: Significance of Solid Predominance. <i>Journal of Thoracic Oncology</i> , 2017, 12, S414-S415.	0.5	1
102	Improved Outcomes with Modern Lung-Sparing Trimodality Therapy in Patients with Malignant Pleural Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 993-1000.	0.5	53
103	CAR T-cell therapy for pancreatic cancer. <i>Journal of Surgical Oncology</i> , 2017, 116, 63-74.	0.8	69
104	Risk stratification for lung nodules: Size isn't everything. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2017, 153, 1557-1562.	0.4	5
105	CAR T-cell intrinsic PD-1 checkpoint blockade: A two-in-one approach for solid tumor immunotherapy. <i>Oncology</i> , 2017, 6, e1273302.	2.1	108
106	Is Repeat Pulmonary Metastasectomy Indicated for Soft Tissue Sarcoma?. <i>Annals of Thoracic Surgery</i> , 2017, 104, 1837-1845.	0.7	28
107	A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma. <i>Clinical Cancer Research</i> , 2017, 23, 7483-7489.	3.2	48
108	Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2017, 29, 416-417.	0.4	0

#	ARTICLE	IF	CITATIONS
109	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. <i>Immunotherapy</i> , 2017, 9, 913-927.	1.0	44
110	The RNA-editing enzyme ADAR promotes lung adenocarcinoma migration and invasion by stabilizing <i>FAK</i> . <i>Science Signaling</i> , 2017, 10, .	1.6	52
111	New Cancer Immunotherapy Agents in Development: a report from an associated program of the 31st Annual Meeting of the Society for Immunotherapy of Cancer, 2016. , 2017, 5, 50.		10
112	Histologic Subtype in Core Lung Biopsies of Early-Stage Lung Adenocarcinoma is a Prognostic Factor for Treatment Response and Failure Patterns After Stereotactic Body Radiation Therapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 138-145.	0.4	43
113	Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Patients With Stage I Non-Small-Cell Lung Cancer: A Competing Risks Analysis. <i>Journal of Clinical Oncology</i> , 2017, 35, 281-290.	0.8	170
114	Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2017, 12, 223-234.	0.5	134
115	Identification and Functional Characterization of <i>EGFR</i> V769M, a Novel Germline Variant Associated With Multiple Lung Adenocarcinomas. <i>JCO Precision Oncology</i> , 2017, 1, 1-10.	1.5	9
116	Micropapillary lung adenocarcinoma and micrometastasis. <i>Journal of Thoracic Disease</i> , 2017, 9, 3443-3446.	0.6	3
117	Immunotherapy for malignant pleural mesothelioma: current status and future directions. <i>Translational Lung Cancer Research</i> , 2017, 6, 315-324.	1.3	30
118	Competing risks analysis in the prognostic assessment of patients undergoing lung resection. <i>Journal of Thoracic Disease</i> , 2017, 9, E395-E397.	0.6	1
119	Cancer antigen profiling for malignant pleural mesothelioma immunotherapy: expression and coexpression of mesothelin, cancer antigen 125, and Wilms tumor 1. <i>Oncotarget</i> , 2017, 8, 77872-77882.	0.8	31
120	Novel immunotherapy clinical trials in malignant pleural mesothelioma. <i>Annals of Translational Medicine</i> , 2017, 5, 245-245.	0.7	6
121	Co-inhibitory receptor programmed cell death protein 1 targets co-stimulatory CD28. <i>Translational Cancer Research</i> , 2017, 6, S1080-S1083.	0.4	2
122	Detection of Recurrence Patterns After Wedge Resection for Early Stage Lung Cancer: Rationale for Radiologic Follow-Up. <i>Annals of Thoracic Surgery</i> , 2016, 102, 1067-1073.	0.7	12
123	Next frontiers in CAR T-cell therapy. <i>Molecular Therapy - Oncolytics</i> , 2016, 3, 16028.	2.0	20
124	KRAS Mutation Is a Significant Prognostic Factor in Early-stage Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2016, 40, 1579-1590.	2.1	50
125	Spread through alveolar spaces: An aerogenous invasion in pulmonary adenocarcinomas. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 73-74.	0.4	3
126	SMART or simply bold?. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 476-477.	0.4	5

#	ARTICLE	IF	CITATIONS
127	Postinduction positron emission tomography assessment of N2 nodes is not associated with ypN2 disease or overall survival in stage IIIA non-small cell lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 151, 969-979.e3.	0.4	23
128	A regional approach for CAR T-cell therapy for mesothelioma: from mouse models to clinical trial. <i>Immunotherapy</i> , 2016, 8, 491-494.	1.0	20
129	Surgical immune interventions for solid malignancies. <i>American Journal of Surgery</i> , 2016, 212, 682-690.e5.	0.9	9
130	Reply to "Uveal melanoma cells are resistant to EZH2 inhibition regardless of BAP1 status". <i>Nature Medicine</i> , 2016, 22, 578-579.	15.2	7
131	Phase II Study of Hemithoracic Intensity-Modulated Pleural Radiation Therapy (IMPRINT) As Part of Lung-Sparing Multimodality Therapy in Patients With Malignant Pleural Mesothelioma. <i>Journal of Clinical Oncology</i> , 2016, 34, 2761-2768.	0.8	154
132	CK2 β ' Drives Lung Cancer Metastasis by Targeting BRMS1 Nuclear Export and Degradation. <i>Cancer Research</i> , 2016, 76, 2675-2686.	0.4	26
133	Scientific Advances in Lung Cancer 2015. <i>Journal of Thoracic Oncology</i> , 2016, 11, 613-638.	0.5	231
134	Pretreatment Dysphagia in Esophageal Cancer Patients May Eliminate the Need for Staging by Endoscopic Ultrasonography. <i>Annals of Thoracic Surgery</i> , 2016, 101, 226-230.	0.7	31
135	Immunotherapy for non-small cell lung cancer: current concepts and clinical trials. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, 1324-1333.	0.6	33
136	Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors. <i>Cancer Discovery</i> , 2016, 6, 133-146.	7.7	359
137	International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification predicts occult lymph node metastasis in clinically mediastinal node-negative lung adenocarcinoma. <i>European Journal of Cardio-thoracic Surgery</i> , 2016, 49, e9-e15.	0.6	64
138	Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. <i>Journal of Clinical Investigation</i> , 2016, 126, 3130-3144.	3.9	773
139	Cell cycle progression score is a marker for five-year lung cancer-specific mortality risk in patients with resected stage I lung adenocarcinoma. <i>Oncotarget</i> , 2016, 7, 35241-35256.	0.8	17
140	Intraoperative subtyping of lung adenocarcinoma: an unmet need. <i>Translational Cancer Research</i> , 2016, 5, S40-S43.	0.4	2
141	Significance of IASLC/ATS/ERS classification for early-stage lung adenocarcinoma patients in predicting benefit from adjuvant chemotherapy. <i>Annals of Translational Medicine</i> , 2016, 4, 66.	0.7	1
142	Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. <i>Chest</i> , 2015, 148, 711-721.	0.4	53
143	Prognostic Impact of Immune Microenvironment in Lung Squamous Cell Carcinoma. <i>Journal of Thoracic Oncology</i> , 2015, 10, 1301-1310.	0.5	47
144	Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. <i>Journal of Thoracic Oncology</i> , 2015, 10, 806-814.	0.5	428

#	ARTICLE	IF	CITATIONS
145	Reevaluation and Reclassification of Resected Lung Carcinomas Originally Diagnosed as Squamous Cell Carcinoma Using Immunohistochemical Analysis. <i>American Journal of Surgical Pathology</i> , 2015, 39, 1170-1180.	2.1	61
146	Small RNA Sequencing for Profiling MicroRNAs in Long-Term Preserved Formalin-Fixed and Paraffin-Embedded Non-Small Cell Lung Cancer Tumor Specimens. <i>PLoS ONE</i> , 2015, 10, e0121521.	1.1	19
147	Design of Wireless Intra-Operative Pulse Oximeter With Reticulated Pressure-Sensitive Head1. <i>Journal of Medical Devices, Transactions of the ASME</i> , 2015, 9, .	0.4	0
148	Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. <i>Lung Cancer</i> , 2015, 89, 329-336.	0.9	11
149	Results of the National Lung Cancer Screening Trial. <i>Thoracic Surgery Clinics</i> , 2015, 25, 145-153.	0.4	25
150	Tumoral CD10 Expression Correlates with Aggressive Histology and Prognosis in Patients with Malignant Pleural Mesothelioma. <i>Annals of Surgical Oncology</i> , 2015, 22, 3136-3143.	0.7	9
151	Solid Predominant Histologic Subtype in Resected Stage I Lung Adenocarcinoma Is an Independent Predictor of Early, Extrathoracic, Multisite Recurrence and of Poor Postrecurrence Survival. <i>Journal of Clinical Oncology</i> , 2015, 33, 2877-2884.	0.8	181
152	Loss of BAP1 function leads to EZH2-dependent transformation. <i>Nature Medicine</i> , 2015, 21, 1344-1349.	15.2	297
153	The tumoral and stromal immune microenvironment in malignant pleural mesothelioma: A comprehensive analysis reveals prognostic immune markers. <i>Oncotarget</i> , 2015, 4, e1009285.	2.1	112
154	Chest Wall Reconstruction Using a Methyl Methacrylate Neo-Rib and Mesh. <i>Annals of Thoracic Surgery</i> , 2015, 100, 744-747.	0.7	20
155	Resection of Primary and Secondary Tumors of the Sternum: An Analysis of Prognostic Variables. <i>Annals of Thoracic Surgery</i> , 2015, 100, 215-222.	0.7	15
156	Using frozen section to identify histological patterns in stage I lung adenocarcinoma of ≤ 3 cm: accuracy and interobserver agreement. <i>Histopathology</i> , 2015, 66, 922-938.	1.6	127
157	Loss of BRMS1 Promotes a Mesenchymal Phenotype through NF- κ B-Dependent Regulation of <i>Twist1</i> . <i>Molecular and Cellular Biology</i> , 2015, 35, 303-317.	1.1	41
158	Nuclear estrogen receptor- β expression is an independent predictor of recurrence in male patients with pT1aNO lung adenocarcinomas, and correlates with regulatory T-cell infiltration. <i>Oncotarget</i> , 2015, 6, 27505-27518.	0.8	21
159	Chylothorax and Recurrent Laryngeal Nerve Injury Associated with Robotic Video-Assisted Mediastinal Lymph Node Dissection. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2015, 10, 170-173.	0.4	0
160	Is spread through alveolar spaces, the newly recognized pattern of invasion, a potential game changer in lung adenocarcinoma?. <i>Annals of Translational Medicine</i> , 2015, 3, 350.	0.7	0
161	Inhibition of Breast Cancer Metastasis Suppressor 1 Promotes a Mesenchymal Phenotype in Lung Epithelial Cells That Express Oncogenic K-RasV12 and Loss of p53. <i>PLoS ONE</i> , 2014, 9, e95869.	1.1	9
162	Mesothelin Expression in Triple Negative Breast Carcinomas Correlates Significantly with Basal-Like Phenotype, Distant Metastases and Decreased Survival. <i>PLoS ONE</i> , 2014, 9, e114900.	1.1	77

#	ARTICLE	IF	CITATIONS
163	Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. <i>Lung Cancer Management</i> , 2014, 3, 245-253.	1.5	12
164	Mesothelin Overexpression Is a Marker of Tumor Aggressiveness and Is Associated with Reduced Recurrence-Free and Overall Survival in Early-Stage Lung Adenocarcinoma. <i>Clinical Cancer Research</i> , 2014, 20, 1020-1028.	3.2	128
165	The New IASLC-ATS-ERS Lung Adenocarcinoma Classification: What the Surgeon Should Know. <i>Seminars in Thoracic and Cardiovascular Surgery</i> , 2014, 26, 210-222.	0.4	76
166	Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. <i>Science Translational Medicine</i> , 2014, 6, 261ra151.	5.8	432
167	Prognostic Significance of Adenocarcinoma In Situ, Minimally Invasive Adenocarcinoma, and Nonmucinous Lepidic Predominant Invasive Adenocarcinoma of the Lung in Patients With Stage I Disease. <i>American Journal of Surgical Pathology</i> , 2014, 38, 448-460.	2.1	214
168	The tumor immune microenvironment in octogenarians with stage I non-small cell lung cancer. <i>Oncolmmunology</i> , 2014, 3, e967142.	2.1	5
169	Comprehensive Pathological Analyses in Lung Squamous Cell Carcinoma: Single Cell Invasion, Nuclear Diameter, and Tumor Budding Are Independent Prognostic Factors for Worse Outcomes. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1126-1139.	0.5	102
170	Associations Between Mutations and Histologic Patterns of Mucin in Lung Adenocarcinoma. <i>American Journal of Surgical Pathology</i> , 2014, 38, 1118-1127.	2.1	131
171	The cribriform pattern identifies a subset of acinar predominant tumors with poor prognosis in patients with stage I lung adenocarcinoma: a conceptual proposal to classify cribriform predominant tumors as a distinct histologic subtype. <i>Modern Pathology</i> , 2014, 27, 690-700.	2.9	121
172	Translational immunotherapeutics: Chemoimmunotherapy for malignant pleural mesothelioma. <i>Cancer</i> , 2014, 120, 3268-3271.	2.0	4
173	Failure Patterns After Hemithoracic Pleural Intensity Modulated Radiation Therapy for Malignant Pleural Mesothelioma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 90, 394-401.	0.4	55
174	Cisplatin-Induced Antitumor Immunomodulation: A Review of Preclinical and Clinical Evidence. <i>Clinical Cancer Research</i> , 2014, 20, 5384-5391.	3.2	240
175	A Prospective Trial Comparing Pain and Quality of Life Measures After Anatomic Lung Resection Using Thoracoscopy or Thoracotomy. <i>Annals of Thoracic Surgery</i> , 2014, 98, 1160-1166.	0.7	101
176	Mesothelin-targeted T Cells Gene-Engineered with 4-1BB Costimulation Overcome Tumor-Mediated Immunoinhibition and Eradicate Established Solid Tumors. <i>Journal of the American College of Surgeons</i> , 2014, 219, S134.	0.2	1
177	Intraoperative Near-Infrared Fluorescence Imaging as an Adjunct to Robotic-Assisted Minimally Invasive Esophagectomy. <i>Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery</i> , 2014, 9, 391-393.	0.4	1
178	Implementing the new IASLC/ATS/ERS classification of lung adenocarcinomas: results from international and Chinese cohorts. <i>Journal of Thoracic Disease</i> , 2014, 6, S568-80.	0.6	10
179	Clinical Impact of Immune Microenvironment in Stage I Lung Adenocarcinoma: Tumor Interleukin-12 Receptor $\beta 2$ (IL-12R $\beta 2$), IL-7R, and Stromal FoxP3/CD3 Ratio Are Independent Predictors of Recurrence. <i>Journal of Clinical Oncology</i> , 2013, 31, 490-498.	0.8	203
180	Preoperative Consolidation-to-Tumor Ratio and SUVmax Stratify the Risk of Recurrence in Patients Undergoing Limited Resection for Lung Adenocarcinoma ≤ 2 cm. <i>Annals of Surgical Oncology</i> , 2013, 20, 4282-4288.	0.7	42

#	ARTICLE	IF	CITATIONS
181	Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: experience, technique and cautions during early procedure development. <i>European Journal of Cardio-thoracic Surgery</i> , 2013, 43, e107-e115.	0.6	85
182	Prognostic value of the immune microenvironment in lung adenocarcinoma. <i>Oncolmmunology</i> , 2013, 2, e24036.	2.1	16
183	Impact of Micropapillary Histologic Subtype in Selecting Limited Resection vs Lobectomy for Lung Adenocarcinoma of 2cm or Smaller. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1212-1220.	3.0	255
184	Thyroid transcription factor-1 expression is an independent predictor of recurrence and correlates with the IASLC/ATS/ERS histologic classification in patients with stage I lung adenocarcinoma. <i>Cancer</i> , 2013, 119, 931-938.	2.0	45
185	Esophageal Cancer Recurrence Patterns and Implications for Surveillance. <i>Journal of Thoracic Oncology</i> , 2013, 8, 1558-1562.	0.5	140
186	Visceral Pleural Invasion Does Not Affect Recurrence or Overall Survival Among Patients With Lung Adenocarcinoma \geq 2 cm. <i>Chest</i> , 2013, 144, 1622-1631.	0.4	37
187	A grading system combining architectural features and mitotic count predicts recurrence in stage I lung adenocarcinoma. <i>Modern Pathology</i> , 2012, 25, 1117-1127.	2.9	148
188	A nuclear grading system is a strong predictor of survival in epithelioid diffuse malignant pleural mesothelioma. <i>Modern Pathology</i> , 2012, 25, 260-271.	2.9	142
189	Tissue and Serum Mesothelin Are Potential Markers of Neoplastic Progression in Barrett's Associated Esophageal Adenocarcinoma. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 482-486.	1.1	39
190	Mesothelin Overexpression Promotes Mesothelioma Cell Invasion and MMP-9 Secretion in an Orthotopic Mouse Model and in Epithelioid Pleural Mesothelioma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 2478-2489.	3.2	159
191	FDG-PET SUVmax Combined with IASLC/ATS/ERS Histologic Classification Improves the Prognostic Stratification of Patients with Stage I Lung Adenocarcinoma. <i>Annals of Surgical Oncology</i> , 2012, 19, 3598-3605.	0.7	93
192	Mesothelin-targeted immunotherapies for malignant pleural mesothelioma. <i>Annals of Cardiothoracic Surgery</i> , 2012, 1, 466-71.	0.6	10
193	Prognostic Immune Markers in Non-Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5247-5256.	3.2	162
194	Fluorescence-Assisted Cytological Testing (FACT): Ex Vivo Viral Method for Enhancing Detection of Rare Cancer Cells in Body Fluids. <i>Molecular Medicine</i> , 2011, 17, 628-634.	1.9	14
195	An In Vivo Platform for Tumor Biomarker Assessment. <i>PLoS ONE</i> , 2011, 6, e26722.	1.1	17
196	Pleomorphic Epithelioid Diffuse Malignant Pleural Mesothelioma: A Clinicopathological Review and Conceptual Proposal to Reclassify as Biphasic or Sarcomatoid Mesothelioma. <i>Journal of Thoracic Oncology</i> , 2011, 6, 896-904.	0.5	110
197	Patterns of recurrence and incidence of second primary tumors after lobectomy by means of video-assisted thoracoscopic surgery (VATS) versus thoracotomy for lung cancer. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 141, 59-64.	0.4	65
198	Video-assisted thoracoscopic surgery (VATS) lobectomy: Catastrophic intraoperative complications. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2011, 142, 1412-1417.	0.4	136

#	ARTICLE	IF	CITATIONS
199	Real-time intraoperative detection of tissue hypoxia in gastrointestinal surgery by wireless pulse oximetry. <i>Surgical Endoscopy and Other Interventional Techniques</i> , 2011, 25, 1383-1389.	1.3	18
200	Animal models and molecular imaging tools to investigate lymph node metastases. <i>Journal of Molecular Medicine</i> , 2011, 89, 753-769.	1.7	23
201	Chronic inflammation in tumor stroma is an independent predictor of prolonged survival in epithelioid malignant pleural mesothelioma patients. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1721-1728.	2.0	70
202	Immune responses and immunotherapeutic interventions in malignant pleural mesothelioma. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 1509-1527.	2.0	50
203	Palliation and Pleurodesis in Malignant Pleural Effusion: The Role for Tunneled Pleural Catheters. <i>Journal of Thoracic Oncology</i> , 2011, 6, 762-767.	0.5	104
204	Preclinical Mouse Models of Primary and Metastatic Pleural Cancers of the Lung and Breast and the Use of Bioluminescent Imaging to Monitor Pleural Tumor Burden. <i>Current Protocols in Pharmacology</i> , 2011, 54, Unit14.21.	4.0	17
205	Frequency of Use and Predictors of Cancer-Directed Surgery in the Management of Malignant Pleural Mesothelioma in a Community-Based (Surveillance, Epidemiology, and End Results [SEER]) Population. <i>Journal of Thoracic Oncology</i> , 2010, 5, 1649-1654.	0.5	75
206	Extracorporeal Membrane Oxygenation for Primary Graft Dysfunction After Lung Transplantation: Long-Term Survival. <i>Annals of Thoracic Surgery</i> , 2009, 87, 854-860.	0.7	136
207	Predictive Value of Initial PET-SUVmax in Patients with Locally Advanced Esophageal and Gastroesophageal Junction Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2009, 4, 875-879.	0.5	80
208	Nectin-1 Expression by Squamous Cell Carcinoma is a Predictor of Herpes Oncolytic Sensitivity. <i>Molecular Therapy</i> , 2007, 15, 103-113.	3.7	54
209	Real-Time Intraoperative Detection of Breast Cancer Axillary Lymph Node Metastases Using a Green Fluorescent Protein-Expressing Herpes Virus. <i>Annals of Surgery</i> , 2006, 243, 824-832.	2.1	33
210	Radiation-Induced Cellular DNA Damage Repair Response Enhances Viral Gene Therapy Efficacy in the Treatment of Malignant Pleural Mesothelioma. <i>Annals of Surgical Oncology</i> , 2006, 14, 258-269.	0.7	44
211	Intraoperative localization of lymph node metastases with a replication-competent herpes simplex virus. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2006, 132, 1179-1188.e1.	0.4	31
212	Imaging and therapy of malignant pleural mesothelioma using replication-competent herpes simplex viruses. <i>Journal of Gene Medicine</i> , 2006, 8, 603-615.	1.4	60
213	Cisplatin-induced GADD34 upregulation potentiates oncolytic viral therapy in the treatment of malignant pleural mesothelioma. <i>Cancer Biology and Therapy</i> , 2006, 5, 48-53.	1.5	57
214	Real-time diagnostic imaging of tumors and metastases by use of a replication-competent herpes vector to facilitate minimally invasive oncological surgery. <i>FASEB Journal</i> , 2006, 20, 726-728.	0.2	50
215	5-Fluorouracil and Gemcitabine Potentiate the Efficacy of Oncolytic Herpes Viral Gene Therapy in the Treatment of Pancreatic Cancer. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1068-1079.	0.9	52
216	Virally Directed Fluorescent Imaging Improves Diagnostic Sensitivity in the Detection of Minimal Residual Disease After Potentially Curative Cytoreductive Surgery. <i>Journal of Gastrointestinal Surgery</i> , 2005, 9, 1138-1147.	0.9	19

#	ARTICLE	IF	CITATIONS
217	Citation Characteristics of Basic Science Research Publications in General Surgical Journals ^{1, 2} . Journal of Surgical Research, 2005, 128, 168-173.	0.8	6
218	Radiation Therapy Potentiates Effective Oncolytic Viral Therapy in the Treatment of Lung Cancer. Annals of Thoracic Surgery, 2005, 80, 409-417.	0.7	50
219	Angiogenesis Inhibition by an Oncolytic Herpes Virus Expressing Interleukin 12. Clinical Cancer Research, 2004, 10, 4509-4516.	3.2	78
220	Infection with Oncolytic Herpes Simplex Virus-1 Induces Apoptosis in Neighboring Human Cancer Cells. Clinical Cancer Research, 2004, 10, 3225-3232.	3.2	53
221	Up-regulation of GADD34 mediates the synergistic anticancer activity of mitomycin C and a β 1 34.5 deleted oncolytic herpes virus (G207). FASEB Journal, 2004, 18, 1001-1003.	0.2	62
222	The prevalence and predictors of herbal medicine use in surgical patients ¹ ¹ No competing interests declared.. Journal of the American College of Surgeons, 2004, 198, 583-590.	0.2	67
223	Left-handed surgeons: Are they left out?. Journal of Surgical Education, 2004, 61, 587-591.	0.7	59
224	Acalculous eosinophilic cholecystitis from herbal medicine: A review of adverse effects of herbal medicine in surgical patients. Surgery, 2002, 131, 352-356.	1.0	22
225	Hemoperitoneum from spontaneous rupture of a liver cell adenoma in a male with hyperthyroidism. American Surgeon, 2002, 68, 582-3.	0.4	42
226	On being a patient in the new millennium. Journal of Family Practice, 2002, 51, 981.	0.2	0